US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
HU225496B1
(en)
|
1993-04-07 |
2007-01-29 |
Scios Inc |
Pharmaceutical compositions of prolonged delivery, containing peptides
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
US6956026B2
(en)
|
1997-01-07 |
2005-10-18 |
Amylin Pharmaceuticals, Inc. |
Use of exendins for the reduction of food intake
|
ATE417622T1
(de)
|
1996-08-08 |
2009-01-15 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
DE69737479D1
(de)
|
1996-08-30 |
2007-04-26 |
Novo Nordisk As |
Glp-1 derivate
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
EP1019077B2
(en)
|
1997-08-08 |
2010-12-22 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
EP1032587B2
(en)
|
1997-11-14 |
2013-03-13 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
AU757748B2
(en)
|
1997-11-14 |
2003-03-06 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
ES2316161T3
(es)
|
1998-01-09 |
2009-04-01 |
Amylin Pharmaceuticals, Inc. |
Formulaciones para peptidos agonistas de amilina con insulina.
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
WO1999046283A1
(en)
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
JP4072319B2
(ja)
|
1998-03-13 |
2008-04-09 |
ノヴォ ノルディスク アクティーゼルスカブ |
安定化水溶性ペプチド溶液
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
ATE270897T1
(de)
|
1998-06-12 |
2004-07-15 |
Amylin Pharmaceuticals Inc |
Glucagonähnliches peptid 1 (glp-1) verbessert die beta zellen antwort auf glukose in patienten mit verminderter glukosetoleranz
|
CA2339326A1
(en)
|
1998-08-10 |
2000-02-24 |
Josephine Egan |
Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
|
BR9913857A
(pt)
|
1998-09-17 |
2001-06-12 |
Lilly Co Eli |
Formulações de proteìna
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
EP1140148B1
(en)
|
1998-12-22 |
2005-10-26 |
Eli Lilly And Company |
Shelf-stable solution formulation of glucagon-like peptide-1
|
DE60044041D1
(de)
|
1999-01-14 |
2010-04-29 |
Amylin Pharmaceuticals Inc |
Exendine zur Glucagon Suppression
|
ES2244416T5
(es)
|
1999-01-14 |
2020-01-03 |
Amylin Pharmaceuticals Llc |
Formulaciones novedosas de agonistas de la exendina y métodos de administración de los mismos
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
RU2001128068A
(ru)
|
1999-03-17 |
2004-02-20 |
Ново Нордиск А/С (DK) |
Способ ацилирования пептидов и новые ацилирующие агенты
|
AU775063C
(en)
|
1999-04-30 |
2005-05-12 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
DE60105547T3
(de)
|
2000-01-10 |
2014-12-31 |
Amylin Pharmaceuticals, Llc |
Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
|
WO2001068112A2
(en)
|
2000-03-14 |
2001-09-20 |
Goeke Burkhard |
Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
|
CA2380423A1
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
EP1282436B1
(en)
|
2000-05-19 |
2008-06-11 |
Amylin Pharmaceuticals, Inc. |
Treatment of acute coronary syndrome with glp-1
|
US7138546B2
(en)
|
2000-08-18 |
2006-11-21 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
MXPA02006118A
(es)
|
2000-10-20 |
2004-08-23 |
Amylin Pharmaceuticals Inc |
Tratamiento de la invernacion del miocardio y cardiopatia diabetica con un peptido glp-1.
|
EA005584B1
(ru)
|
2000-12-07 |
2005-04-28 |
Эли Лилли Энд Компани |
Слитые белки glp-1
|
US7259233B2
(en)
|
2000-12-13 |
2007-08-21 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
EP1542712A2
(en)
|
2001-06-01 |
2005-06-22 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
AU2002316811A1
(en)
|
2001-06-28 |
2003-03-03 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
CA2652991A1
(en)
|
2001-07-16 |
2003-11-13 |
Caprotec Bioanalytics Gmbh |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
JP2005508895A
(ja)
|
2001-08-28 |
2005-04-07 |
イーライ・リリー・アンド・カンパニー |
Glp−1および基礎インスリンの予備混合物
|
CA2463803A1
(en)
|
2001-10-19 |
2003-05-01 |
Eli Lilly And Company |
Biphasic mixtures of glp-1 and insulin
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1463752A4
(en)
|
2001-12-21 |
2005-07-13 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
WO2003072195A2
(en)
|
2002-02-20 |
2003-09-04 |
Eli Lilly And Company |
Method for administering glp-1 molecules
|
AU2003219958B2
(en)
|
2002-02-27 |
2006-01-05 |
Immunex Corporation |
Polypeptide formulation
|
AU2003224674A1
(en)
|
2002-03-11 |
2003-09-29 |
Hk Pharmaceuticals, Inc. |
Compounds and methods for analyzing the proteome
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
EP1494704A1
(en)
|
2002-04-04 |
2005-01-12 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
BR0308904A
(pt)
|
2002-04-10 |
2005-05-03 |
Lilly Co Eli |
Método de tratamento de gastroparesia, e, uso de um composto de glp-1
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
WO2003105897A1
(en)
|
2002-06-14 |
2003-12-24 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
CA2491478A1
(en)
|
2002-07-09 |
2004-01-15 |
Sandoz Ag |
Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
EP1545457A4
(en)
|
2002-08-01 |
2009-07-01 |
Mannkind Corp |
CELL TRANSPORT COMPOSITIONS AND ITS USES
|
PT1532149E
(pt)
|
2002-08-21 |
2010-02-17 |
Boehringer Ingelheim Pharma |
8-[3-amino-piperidinil-1-il]-xantinas, sua preparação e sua utilização como produto farmacêutico
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
MXPA05003335A
(es)
|
2002-10-02 |
2005-07-05 |
Zealand Pharma As |
Compuestos de exendina-4 estabilizados.
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
AU2003280117B2
(en)
|
2002-11-20 |
2009-09-10 |
Newron Sweden Ab |
Compounds and methods for increasing neurogenesis
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
WO2004056313A2
(en)
|
2002-12-17 |
2004-07-08 |
Amylin Pharmaceuticals, Inc. |
Prevention and treatment of cardiac arrhythmias
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
CA2521784C
(en)
|
2003-04-08 |
2012-03-27 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
WO2004103390A2
(en)
|
2003-05-15 |
2004-12-02 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
AU2004251602B2
(en)
|
2003-05-23 |
2010-05-13 |
Nektar Therapeutics |
PEG derivatives having an amidocarbonate linkage
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
ES2425221T3
(es)
|
2003-05-30 |
2013-10-14 |
Amylin Pharmaceuticals, Llc |
Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
|
CN1812808B
(zh)
|
2003-06-03 |
2012-07-04 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
JP4936884B2
(ja)
|
2003-06-03 |
2012-05-23 |
ノボ・ノルデイスク・エー/エス |
安定化された薬学的ペプチド組成物
|
EP1633390B1
(en)
|
2003-06-03 |
2012-01-18 |
Novo Nordisk A/S |
Stabilized pharmaceutical glp-1 peptide compositions
|
PL1633391T3
(pl)
|
2003-06-03 |
2012-03-30 |
Novo Nordisk As |
Stabilizowane farmaceutycznie kompozycje peptydowe
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
EP2264065B1
(en)
|
2003-08-05 |
2017-03-08 |
Novo Nordisk A/S |
Novel insulin derivatives
|
RU2006103860A
(ru)
|
2003-08-21 |
2006-07-27 |
Ново Нордиск А/С (DK) |
Способ разделения полипептидов, содержащих рацемическую аминокислоту
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
JP5518282B2
(ja)
|
2003-09-01 |
2014-06-11 |
ノヴォ ノルディスク アー/エス |
安定なペプチドの製剤
|
TW200522976A
(en)
|
2003-09-19 |
2005-07-16 |
Novo Nordisk As |
Novel plasma protein affinity tags
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
JP4800959B2
(ja)
|
2003-11-13 |
2011-10-26 |
ノヴォ ノルディスク アー/エス |
糖尿病及び過食症を治療するためのglp−1ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
PL1687019T3
(pl)
|
2003-11-20 |
2018-05-30 |
Novo Nordisk A/S |
Formulacje peptydowe zawierające glikol propylenowy, które są optymalne do produkcji i do zastosowania w urządzeniach do wstrzykiwań
|
EP1750752A2
(en)
|
2003-11-20 |
2007-02-14 |
Neuronova AB |
Compounds and methods for increasing neurogenesis
|
CN1902226A
(zh)
|
2003-12-03 |
2007-01-24 |
诺和诺德公司 |
单链胰岛素
|
CA2549011A1
(en)
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
CN1938334A
(zh)
*
|
2004-01-30 |
2007-03-28 |
瓦拉塔药品公司 |
Glp-1激动剂和胃泌素化合物的联合使用
|
JP5638177B2
(ja)
|
2004-02-11 |
2014-12-10 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
ES2345113T3
(es)
|
2004-02-11 |
2010-09-15 |
Amylin Pharmaceuticals, Inc. |
Peptidos de la familia amilina y metodos para su obtencion y utilizacion.
|
CN102174115B
(zh)
|
2004-02-11 |
2014-05-14 |
安米林药品有限责任公司 |
具有可选择特性的杂合多肽
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
JP5030292B2
(ja)
|
2004-04-15 |
2012-09-19 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
ポリマーを基にした持続放出性装置
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
EP2316446A1
(en)
|
2004-06-11 |
2011-05-04 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
RU2393168C2
(ru)
|
2004-07-19 |
2010-06-27 |
Биокон Лимитед |
Инсулин-олигомерные конъюгаты, их препараты и применения
|
BRPI0512396A
(pt)
|
2004-07-21 |
2008-03-11 |
Ambrx Inc |
polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
|
KR20070085224A
(ko)
|
2004-08-03 |
2007-08-27 |
바이오렉시스 파마슈티칼 코포레이션 |
Glp-1을 포함하는 트랜스페린 융합 단백질을 사용하는혼합 요법
|
CA2577158A1
(en)
|
2004-08-16 |
2006-02-23 |
Water Un Limited |
Apparatus and method for cooling of air
|
PL1789434T3
(pl)
|
2004-08-31 |
2014-07-31 |
Novo Nordisk As |
Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
US8143391B2
(en)
|
2004-09-07 |
2012-03-27 |
Chugai Seiyaku Kabushiki Kaisha |
Process for producing water-soluble hyaluronic acid modification
|
EP1791554A2
(en)
|
2004-09-17 |
2007-06-06 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
KR101506925B1
(ko)
|
2004-10-01 |
2015-03-30 |
램스코르 인코포레이티드 |
편리하게 이식가능한 서방형 약물 조성물
|
US8030273B2
(en)
|
2004-10-07 |
2011-10-04 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
US20060089325A1
(en)
|
2004-10-13 |
2006-04-27 |
Sanjay Bhanot |
Antisense modulation of PTP1B expression
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
MX2007005521A
(es)
|
2004-11-12 |
2007-05-18 |
Novo Nordisk As |
Formulaciones estables de peptidos insulinotropicos.
|
US20090011976A1
(en)
|
2004-11-12 |
2009-01-08 |
Novo Nordisk A/S |
Stable Formulations Of Peptides
|
CN101056650A
(zh)
|
2004-11-12 |
2007-10-17 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
EP2769990A3
(en)
|
2004-12-02 |
2015-02-25 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
|
EP3000826A1
(en)
|
2004-12-13 |
2016-03-30 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
MX2007007471A
(es)
|
2004-12-21 |
2007-07-20 |
Nektar Therapeutics Al Corp |
Reactivos de tiol polimericos estabilizados.
|
WO2006068910A1
(en)
|
2004-12-22 |
2006-06-29 |
Eli Lilly And Company |
Glp-1 analog fusion protein formulations
|
AU2005323063B2
(en)
|
2004-12-24 |
2011-01-27 |
Amylin Pharmaceuticals, Llc |
Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
EP1845105A4
(en)
|
2005-01-14 |
2009-02-18 |
Wuxi Grandchamp Pharmaceutical |
MODIFIED EXENDINES AND CORRESPONDING USES
|
US20080233053A1
(en)
|
2005-02-07 |
2008-09-25 |
Pharmalight Inc. |
Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
|
SG159551A1
(en)
|
2005-02-11 |
2010-03-30 |
Amylin Pharmaceuticals Inc |
Gip analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
ATE550032T1
(de)
|
2005-04-11 |
2012-04-15 |
Amylin Pharmaceuticals Inc |
Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung
|
US20090043264A1
(en)
|
2005-04-24 |
2009-02-12 |
Novo Nordisk A/S |
Injection Device
|
CN101180081B
(zh)
|
2005-05-25 |
2015-08-26 |
诺沃-诺迪斯克有限公司 |
稳定的多肽制剂
|
AU2006249869A1
(en)
|
2005-05-26 |
2006-11-30 |
Bristol-Myers Squibb Company |
N-terminally modified GLP-1 receptor modulators
|
EP1888031B1
(en)
|
2005-06-06 |
2013-01-23 |
Camurus Ab |
Glp-1 analogue formulations
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
CA2612063A1
(en)
|
2005-06-13 |
2006-12-21 |
Imperial Innovations Limited |
Oxyntomodulin analogues and their effects on feeding behaviour
|
EP1896082B1
(en)
|
2005-06-16 |
2012-12-26 |
Nektar Therapeutics |
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
|
AU2006278490A1
(en)
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics |
Conjugates of a G-CSF moiety and a polymer
|
US8278420B2
(en)
|
2005-08-06 |
2012-10-02 |
Qinghua Wang |
Composition and method for prevention and treatment of type I diabetes
|
EP1922336B1
(en)
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
PL2347762T3
(pl)
|
2005-08-19 |
2019-09-30 |
Amylin Pharmaceuticals, Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
MX358592B
(es)
|
2005-09-14 |
2018-08-27 |
Mannkind Corp |
Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
|
RU2440143C2
(ru)
|
2005-09-20 |
2012-01-20 |
Новартис Аг |
Применение ингибитора dpp-iv для снижения приступов гликемии
|
US8759290B2
(en)
|
2005-10-18 |
2014-06-24 |
Biocon Limited |
Oral glucagon-like peptide conjugates for metabolic diseases
|
WO2007047922A2
(en)
|
2005-10-19 |
2007-04-26 |
Smartcells, Inc. |
Polymer-drug conjugates
|
WO2007056362A2
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
JP2009518315A
(ja)
|
2005-12-02 |
2009-05-07 |
エムディーアールエヌエー,インコーポレイテッド |
グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
|
CA2632903C
(en)
|
2005-12-02 |
2015-11-24 |
Vianova Labs, Inc. |
Treatment of cancer and other diseases
|
WO2007067964A2
(en)
|
2005-12-08 |
2007-06-14 |
Nastech Pharmaceutical Company Inc. |
Mucosal delivery of stabilized formulations of exendin
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
ES2779992T3
(es)
|
2005-12-20 |
2020-08-21 |
Univ Duke |
Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
|
MX2008009125A
(es)
|
2006-01-18 |
2008-10-23 |
Qps Llc |
Composiciones farmaceuticas con estabilidad mejorada.
|
US20080071063A1
(en)
|
2006-02-03 |
2008-03-20 |
Medimmune, Inc. |
Protein Formulations
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
CN101432025B
(zh)
|
2006-03-21 |
2012-04-04 |
安米林药品公司 |
肽-肽酶抑制剂结合物及其使用方法
|
US20100087365A1
(en)
|
2006-04-13 |
2010-04-08 |
Roland Cherif-Cheikh |
Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
|
KR101438839B1
(ko)
|
2006-04-14 |
2014-10-02 |
맨카인드 코포레이션 |
글루카곤 유사 펩타이드 1 (glp-1) 약제학적 제제
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP2029160A2
(en)
|
2006-05-12 |
2009-03-04 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
CA2652907A1
(en)
|
2006-05-26 |
2007-12-06 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treatment of diabetes
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
EP2038423B1
(en)
|
2006-06-21 |
2012-12-26 |
Biocon Limited |
A method of producing biologically active polypeptide having insulinotropic activity
|
PT2494959E
(pt)
|
2006-07-05 |
2015-02-20 |
Foamix Pharmaceuticals Ltd |
Veículo formador de espuma de ácido dicarboxílico e suas composições farmacêuticas
|
WO2008012629A2
(en)
|
2006-07-24 |
2008-01-31 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
WO2008016729A1
(en)
|
2006-08-04 |
2008-02-07 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
EP2359808B1
(en)
|
2006-08-09 |
2013-05-22 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
CA2660835A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable propperties
|
EP2057189B1
(en)
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
CN102827284B
(zh)
|
2006-11-14 |
2015-07-29 |
上海仁会生物制药股份有限公司 |
带有聚乙二醇基团的Exendin或其类似物及其制剂和用途
|
EP2124883A2
(en)
|
2006-12-12 |
2009-12-02 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical formulations and methods for making the same
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
ES2628063T3
(es)
|
2007-01-05 |
2017-08-01 |
Indiana University Research And Technology Corporation |
Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
CN101663317A
(zh)
*
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
KR20090119876A
(ko)
|
2007-02-15 |
2009-11-20 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
CN105688191A
(zh)
|
2007-04-23 |
2016-06-22 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
US9353170B2
(en)
|
2007-06-08 |
2016-05-31 |
Sanofi-Aventis Deutschland Gmbh |
Long-acting transient polymer conjugates of exendin
|
US7994122B2
(en)
|
2007-06-15 |
2011-08-09 |
Zealand Pharma A/S |
Glucagon analogues
|
ATE499088T1
(de)
|
2007-07-10 |
2011-03-15 |
Lilly Co Eli |
Glp-1-fc fusionsprotein-formulierung
|
ES2646614T3
(es)
|
2007-08-03 |
2017-12-14 |
Eli Lilly And Company |
Uso de un compuesto de FGF 21 y un compuesto de GLP 1 para el tratamiento de la obesidad
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
KR20100080519A
(ko)
|
2007-08-30 |
2010-07-08 |
큐어디엠 인코포레이티드 |
프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
|
WO2009030771A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
EP2650006A1
(en)
|
2007-09-07 |
2013-10-16 |
Ipsen Pharma S.A.S. |
Analogues of exendin-4 and exendin-3
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
WO2009055742A2
(en)
|
2007-10-24 |
2009-04-30 |
Mannkind Corporation |
Delivery of active agents
|
ES2547529T3
(es)
|
2007-10-24 |
2015-10-07 |
Mannkind Corporation |
Formulación en polvo seco inhalable que comprende GLP-1 para usar en el tratamiento de la hiperglucemia y diabetes por administración pulmonar
|
JP5669582B2
(ja)
|
2007-10-30 |
2015-02-12 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト
|
MX2010004298A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
|
US8937042B2
(en)
|
2007-11-16 |
2015-01-20 |
Novo Nordisk A/S |
Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
|
EP2224945B1
(en)
|
2007-11-23 |
2012-05-16 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
WO2009075859A2
(en)
|
2007-12-11 |
2009-06-18 |
Conjuchem Biotechnologies Inc. |
Formulation of insulinotropic peptide conjugates
|
CN102007143B
(zh)
|
2008-01-09 |
2015-08-26 |
塞诺菲-安万特德国有限公司 |
具有超延迟时效特征的新型胰岛素衍生物
|
CN101983066B
(zh)
|
2008-01-30 |
2016-06-29 |
印第安那大学科技研究公司 |
基于酯的胰岛素前药
|
DK2237799T3
(da)
|
2008-02-01 |
2019-06-11 |
Ascendis Pharma As |
Prodrug omfattende en selv-spaltbar linker
|
MX2010008654A
(es)
|
2008-02-06 |
2010-10-06 |
Biocon Ltd |
Medios de fermentacion y procedimientos para los mismos.
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
AU2008354530B2
(en)
|
2008-04-07 |
2014-02-27 |
Indian Institute Of Science |
Compositions useful for the treatment of diabetes and other chronic disorder
|
CA2723541A1
(en)
|
2008-05-07 |
2009-11-12 |
Merrion Research Iii Limited |
Compositions of peptides and processes of preparation thereof
|
EP2303313B1
(en)
|
2008-05-21 |
2015-10-28 |
Amylin Pharmaceuticals, LLC |
Exendins to lower cholestrol and triglycerides
|
EP2288918A1
(en)
|
2008-05-23 |
2011-03-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
KR101548092B1
(ko)
|
2008-06-13 |
2015-08-27 |
맨카인드 코포레이션 |
건조 분말 흡입기 및 약물 투여 시스템
|
CN103641907A
(zh)
|
2008-06-17 |
2014-03-19 |
印第安纳大学研究及科技有限公司 |
胰高血糖素/glp-1受体共激动剂
|
US8765669B2
(en)
|
2008-06-17 |
2014-07-01 |
Glytech, Inc. |
Glycosylated GLP-1 peptide
|
CA2727161A1
(en)
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
MX2010013453A
(es)
|
2008-06-17 |
2011-01-21 |
Univ Indiana Res & Tech Corp |
Agonistas mezclados basados en gip para el tratamiento de desordenes metabolicos y obesidad.
|
EP2926825A1
(en)
|
2008-06-27 |
2015-10-07 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
WO2010010555A2
(en)
|
2008-07-21 |
2010-01-28 |
Transpharma Medical Ltd. |
Transdermal system for extended delivery of incretins and incretin mimetic peptides
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
MX344293B
(es)
|
2008-10-17 |
2016-12-13 |
Sanofi Aventis Deutschland |
Combinacion de una insulina y un agonista de glp-1.
|
WO2010068735A1
(en)
|
2008-12-10 |
2010-06-17 |
Glaxosmithkline Llc. |
Pharmaceutical compositions
|
EA020497B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
EP2370462B1
(en)
|
2008-12-15 |
2014-07-16 |
Zealand Pharma A/S |
Glucagon analogues
|
US8685919B2
(en)
|
2008-12-15 |
2014-04-01 |
Zealand Pharma A/S |
Glucagon analogues
|
CN102292347A
(zh)
|
2008-12-15 |
2011-12-21 |
西兰制药公司 |
胰高血糖素类似物
|
KR20110110174A
(ko)
|
2008-12-19 |
2011-10-06 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
DE102009006602A1
(de)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
CA2791847C
(en)
|
2009-03-04 |
2017-05-02 |
Mannkind Corporation |
An improved dry powder drug delivery system
|
JP5608686B2
(ja)
|
2009-03-05 |
2014-10-15 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
後退可能な針を備えた薬物送達デバイス
|
EP2413955A4
(en)
|
2009-04-01 |
2012-12-26 |
Amylin Pharmaceuticals Inc |
AGONIST COMPOUNDS OF GLP-1 RECEPTORS HAVING CONFORMATIONAL CONSTRAINTS AT THEIR N-TERMINAL END
|
WO2010118034A2
(en)
|
2009-04-06 |
2010-10-14 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
RU2503688C2
(ru)
|
2009-04-22 |
2014-01-10 |
Алтеоген, Инк |
Слитый белок или пептид с увеличенным временем полужизни in vivo, поддерживаемый за счет замедленного высвобождения in vivo, и способ увеличения времени полужизни in vivo с его применением
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
US9855389B2
(en)
|
2009-05-20 |
2018-01-02 |
Sanofi-Aventis Deutschland Gmbh |
System comprising a drug delivery device and a cartridge provided with a bung and a method of identifying the cartridge
|
BRPI1012786A2
(pt)
|
2009-05-20 |
2019-09-24 |
Safoni Aventis Deutschland Gmbh |
"batoque para cartuchos de contenção de fármaco em dispositivo de administração de fármaco"
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
EP2440235A1
(en)
|
2009-06-11 |
2012-04-18 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
WO2010148089A1
(en)
|
2009-06-16 |
2010-12-23 |
Indiana University Research And Technology Corporation |
Gip receptor-active glucagon compounds
|
US9161988B2
(en)
|
2009-07-02 |
2015-10-20 |
Angiochem Inc. |
Multimeric peptide conjugates and uses thereof
|
JP6054742B2
(ja)
|
2009-07-13 |
2016-12-27 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
CA2769340C
(en)
|
2009-07-31 |
2018-09-11 |
Harald Rau |
Prodrugs comprising an insulin linker conjugate
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
CN102666586A
(zh)
|
2009-09-30 |
2012-09-12 |
葛兰素集团有限公司 |
具有延长的半衰期的药物融合体和缀合物
|
WO2011049713A2
(en)
|
2009-10-22 |
2011-04-28 |
Biodel Inc. |
Stabilized glucagon solutions
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
AU2010312655A1
(en)
|
2009-10-30 |
2012-05-03 |
Glytech, Inc. |
Glycosylated form of antigenic GLP-1 analogue
|
EP2496583B1
(en)
|
2009-11-02 |
2014-12-10 |
Pfizer Inc |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
EP2496249B1
(en)
|
2009-11-03 |
2016-03-09 |
Amylin Pharmaceuticals, LLC |
Glp-1 receptor agonist for use in treating obstructive sleep apnea
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
KR101772372B1
(ko)
|
2009-11-13 |
2017-08-29 |
사노피-아벤티스 도이칠란트 게엠베하 |
Glp-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
|
EP2512475A1
(en)
|
2009-12-15 |
2012-10-24 |
Metabolic Solutions Development Company LLC |
Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases
|
PL2512470T3
(pl)
|
2009-12-15 |
2017-06-30 |
Octeta Therapeutics, Llc |
Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych
|
MX2012006725A
(es)
|
2009-12-15 |
2012-06-28 |
Metabolic Solutions Dev Co Llc |
Sales de tiazolidinadiona reductoras de receptores activados por proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas.
|
CA2783264A1
(en)
|
2009-12-15 |
2011-07-14 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases
|
ES2561658T3
(es)
|
2009-12-16 |
2016-02-29 |
Novo Nordisk A/S |
Derivados de GLP-1 con doble acilación
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
CN101798588B
(zh)
*
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
MX342409B
(es)
|
2010-01-20 |
2016-09-28 |
Zealand Pharma As |
Tratamiento de enfermedades cardiacas.
|
EP2528618A4
(en)
*
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
|
EP3782677A1
(en)
|
2010-02-01 |
2021-02-24 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with cartridge holder
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
AU2011232335A1
(en)
|
2010-03-24 |
2012-10-11 |
Shifamed Holdings, Llc |
Intravascular tissue disruption
|
KR20130018410A
(ko)
|
2010-03-26 |
2013-02-21 |
노보 노르디스크 에이/에스 |
새로운 글루카곤 유사체
|
AR080592A1
(es)
*
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
JP6050746B2
(ja)
|
2010-05-13 |
2016-12-21 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
|
JP6121323B2
(ja)
|
2010-05-13 |
2017-05-10 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
EA201291009A1
(ru)
|
2010-05-20 |
2013-05-30 |
Глаксо Груп Лимитед |
Улучшенные связывающие варианты против сывороточного альбумина
|
US8263554B2
(en)
|
2010-06-09 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
Methods of using GLP-1 receptor agonists to treat pancreatitis
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
CN102985125A
(zh)
|
2010-06-21 |
2013-03-20 |
曼金德公司 |
干粉药物输送系统和方法
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
US9234023B2
(en)
|
2010-06-24 |
2016-01-12 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
EP2588126A4
(en)
|
2010-06-24 |
2015-07-08 |
Univ Indiana Res & Tech Corp |
GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
US20130137645A1
(en)
|
2010-07-19 |
2013-05-30 |
Mary S. Rosendahl |
Modified peptides and proteins
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
CA2806749A1
(en)
|
2010-07-28 |
2012-02-02 |
Amylin Pharmaceuticals, Llc |
Glp-1 receptor agonist compounds having stabilized regions
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
WO2012050923A2
(en)
|
2010-09-28 |
2012-04-19 |
Amylin Pharmaceuticals, Inc. |
Engineered polypeptides having enhanced duration of action
|
ES2533601T3
(es)
|
2010-11-03 |
2015-04-13 |
Arecor Limited |
Nueva composición que comprende glucagón
|
CN107854454A
(zh)
|
2010-11-09 |
2018-03-30 |
曼金德公司 |
用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
CN102552883B
(zh)
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
RU2600440C3
(ru)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
|
MA34885B1
(fr)
|
2010-12-22 |
2014-02-01 |
Indiana Unversity Res And Technology Corp |
Analogues du glucagon presentant una ctivite de recepteur de gip
|
US9161953B2
(en)
|
2010-12-22 |
2015-10-20 |
Amylin Pharmaceuticals, Llc |
GLP-1 receptor agonists for islet cell transplantation
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
CN105853348B
(zh)
|
2011-03-10 |
2019-08-30 |
Xeris药物公司 |
肠胃外注射用稳定溶液
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
CN102718868A
(zh)
|
2011-03-30 |
2012-10-10 |
上海华谊生物技术有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
EP2694095B1
(en)
|
2011-04-05 |
2018-03-07 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
WO2012140647A2
(en)
|
2011-04-11 |
2012-10-18 |
Yeda Research And Development Co. Ltd |
Albumin binding probes and drug conjugates thereof
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
WO2012158965A2
(en)
|
2011-05-18 |
2012-11-22 |
Mederis Diabetes, Llc |
Improved peptide pharmaceuticals for insulin resistance
|
WO2012162547A2
(en)
|
2011-05-25 |
2012-11-29 |
Amylin Pharmaceuticals, Inc. |
Long duration dual hormone conjugates
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
RU2612906C2
(ru)
|
2011-06-10 |
2017-03-13 |
Ханми Сайенс Ко., Лтд. |
Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения
|
KR102002783B1
(ko)
|
2011-06-10 |
2019-07-24 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
|
TWI601744B
(zh)
|
2011-06-17 |
2017-10-11 |
韓美科學股份有限公司 |
包含調酸素與免疫球蛋白片段之複合物及其用途
|
EA201400031A1
(ru)
|
2011-06-17 |
2014-07-30 |
Галозим, Инк. |
Стабильные составы на основе фермента, разрушающего хиалуронан
|
JP6184404B2
(ja)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン/glp−1レセプターコアゴニスト
|
KR101972617B1
(ko)
|
2011-06-22 |
2019-04-25 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진제들
|
WO2012177929A2
(en)
|
2011-06-24 |
2012-12-27 |
Amylin Pharmaceuticals, Inc. |
Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
WO2013004983A1
(en)
|
2011-07-04 |
2013-01-10 |
Imperial Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
EP2729481B1
(en)
|
2011-07-08 |
2018-10-17 |
Amylin Pharmaceuticals, LLC |
Engineered polypeptides having enhanced duration of action with reduced immunogenicity
|
KR101810055B1
(ko)
|
2011-08-10 |
2017-12-18 |
아도시아 |
하나 이상의 유형의 기저 인슐린의 주사액
|
EP4295858A1
(en)
|
2011-08-24 |
2023-12-27 |
ImmunoForge Co., Ltd. |
Formulations of active agents for sustained release
|
WO2013029279A1
(zh)
|
2011-09-03 |
2013-03-07 |
深圳市健元医药科技有限公司 |
新的glp-ⅰ类似物及其制备方法和用途
|
IN2014CN02448A
(ja)
|
2011-09-23 |
2015-06-19 |
Novo Nordisk As |
|
EP2771024B1
(en)
|
2011-10-28 |
2018-11-28 |
Sanofi-Aventis Deutschland GmbH |
Treatment protocol of diabetes type 2
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
BR112014007124A2
(pt)
|
2011-11-17 |
2017-06-13 |
Univ Indiana Res & Tech Corp |
superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
|
CN107261152B
(zh)
|
2011-11-29 |
2022-03-04 |
优奥斯私人有限公司 |
包含环糊精和疏水性药物的可注射药物组合物的防腐方法
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
WO2013093720A2
(en)
|
2011-12-22 |
2013-06-27 |
Pfizer Inc. |
Anti-diabetic compounds
|
WO2013092703A2
(en)
|
2011-12-23 |
2013-06-27 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2013101749A1
(en)
|
2011-12-29 |
2013-07-04 |
Latitude Pharmaceuticals, Inc. |
Stabilized glucagon nanoemulsions
|
CN107583039A
(zh)
|
2012-01-09 |
2018-01-16 |
阿道恰公司 |
Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
EP2844269A4
(en)
|
2012-03-28 |
2016-01-06 |
Amylin Pharmaceuticals Llc |
TRANSMUCULOUS ADMINISTRATION OF GENETICALLY MODIFIED POLYPEPTIDES
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
EP2833923A4
(en)
|
2012-04-02 |
2016-02-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
WO2013163162A1
(en)
|
2012-04-24 |
2013-10-31 |
Amylin Pharmaceuticals, Llc |
Site-specific enzymatic modification of exendins and analogs thereof
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
US9453064B2
(en)
|
2012-05-03 |
2016-09-27 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
CN104470948B
(zh)
|
2012-05-03 |
2018-06-15 |
西兰制药公司 |
Gip-glp-1双激动剂化合物及方法
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
US20150174209A1
(en)
|
2012-05-25 |
2015-06-25 |
Amylin Pharmaceuticals. Llc |
Insulin-pramlintide compositions and methods for making and using them
|
AR091422A1
(es)
|
2012-06-14 |
2015-02-04 |
Sanofi Sa |
Analogos peptidicos de la exendina 4
|
AR091477A1
(es)
|
2012-06-21 |
2015-02-04 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que presentan actividad de receptor de gip
|
RS57347B1
(sr)
|
2012-06-21 |
2018-08-31 |
Univ Indiana Res & Tech Corp |
Analozi glukagona koji ispoljavaju aktivnost gip receptora
|
RU2650035C2
(ru)
|
2012-07-12 |
2018-04-06 |
Маннкайнд Корпорейшн |
Системы и способы доставки сухих порошковых лекарств
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
EP2934562A1
(en)
|
2012-08-14 |
2015-10-28 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
EP2931300A1
(en)
|
2012-08-14 |
2015-10-21 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
US9546205B2
(en)
|
2012-09-17 |
2017-01-17 |
Imperial Innovations Limited |
Peptide analogues of glucagon and GLP1
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
TWI602583B
(zh)
|
2012-11-06 |
2017-10-21 |
韓美藥品股份有限公司 |
包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
CN117903257A
(zh)
|
2012-11-20 |
2024-04-19 |
梅德瑞斯糖尿病有限责任公司 |
用于胰岛素抗性的改良的肽药物
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
CN104902919B
(zh)
|
2012-12-21 |
2018-11-20 |
赛诺菲 |
Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
US9714277B2
(en)
|
2013-03-14 |
2017-07-25 |
Medimmune Limited |
Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
|
BR112015023071A2
(pt)
|
2013-03-14 |
2017-07-18 |
Univ Indiana Res & Tech Corp |
conjugados de insulina-incretina
|
EP2986314A4
(en)
|
2013-03-15 |
2016-04-13 |
Univ Indiana Res & Tech Corp |
PROTOCOLS AND A PROLONGED ACTION
|
RS59124B1
(sr)
|
2013-04-18 |
2019-09-30 |
Novo Nordisk As |
Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
UA122767C2
(uk)
|
2013-10-17 |
2021-01-06 |
Зіленд Фарма А/С |
Ацильований аналог глюкагону
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
EA035688B1
(ru)
|
2013-11-06 |
2020-07-27 |
Зилэнд Фарма А/С |
Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
|
WO2015086732A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
WO2015086731A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽-4(exendin-4)胜肽類似物
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
AU2015205624A1
(en)
|
2014-01-09 |
2016-07-14 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
CA2932875A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
GB201404002D0
(en)
|
2014-03-06 |
2014-04-23 |
Imp Innovations Ltd |
Novel compounds
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自exendin-4之雙重glp-1/升糖素受體促效劑
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
CN106519015B
(zh)
|
2014-09-23 |
2020-04-17 |
深圳市图微安创科技开发有限公司 |
胃泌酸调节素类似物
|
EP3204408B1
(en)
|
2014-10-10 |
2020-05-06 |
Novo Nordisk A/S |
Stable glp-1 based glp-1/glucagon receptor co-agonists
|
EA201790914A1
(ru)
|
2014-10-24 |
2017-08-31 |
Мерк Шарп И Доум Корп. |
Коагонисты рецепторов глюкагона и glp-1
|
WO2016198604A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
|